RxDoctor Payments Data

Gina Bachmann, MD

Family Medicine · Powell, OHNPI 1801887989

Payments from drug & device makers

$1,268in general payments, 2019–2025

Across 26 payments — averaging $48.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$522
  • Novo Nordisk$364
  • Amgen$116
  • Boehringer Ingelheim$88
  • Sunovion Pharmaceuticals Inc.$46
  • Merck$36
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$1,268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,268 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$31,766
Medicare patients
94
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide26$61,891
EliquisApixaban35$51,363
OzempicSemaglutide33$39,725
FarxigaDapagliflozin Propanediol13$17,962
Arnuity ElliptaFluticasone Furoate14$2,771
Rosuvastatin Calcium102$2,533
Atorvastatin Calcium215$2,114
Losartan Potassium153$1,461
SynthroidLevothyroxine Sodium20$1,357
Omeprazole100$1,122
Levothyroxine Sodium105$1,015
Lisinopril175$998
Gabapentin37$895
Metoprolol Succinate71$874
Valsartan20$822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$364$101,61659 claims
AstraZenecaFarxiga$522$17,96213 claims
GSKArnuity Ellipta$19$2,77114 claims
AbbVieSynthroid$28$1,35720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Powell

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →